



## Renalytix to Present at Stifel Healthcare Conference

November 3, 2022

NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the Company's website at <https://investors.renalytix.com> or via the webcast registration link below beginning at 3:35 p.m. Eastern Time on November 16, 2022.

Webcast registration link: <https://wsw.com/webcast/stifel74/rnlx/2129288>

### About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit [www.kidneyintelx.com](http://www.kidneyintelx.com)). For more information, visit [www.renalytix.com](http://www.renalytix.com).

### For further information, please contact:

#### Renalytix plc

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

#### Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore

Tel: 020 7710 7600

#### Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams

Tel: 020 7597 4000

#### Walbrook PR Limited

Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

#### CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)